Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1986 1
1993 1
2002 1
2004 2
2005 3
2006 3
2007 5
2008 5
2009 7
2010 14
2011 7
2012 5
2013 7
2014 8
2015 4
2016 4
2017 8
2018 3
2019 6
2020 4
2021 7
2022 9
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. Among authors: el beshlawy a. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E. Howard J, et al. Among authors: el beshlawy a. Lancet Haematol. 2021 May;8(5):e323-e333. doi: 10.1016/S2352-3026(21)00059-4. Epub 2021 Apr 7. Lancet Haematol. 2021. PMID: 33838113 Clinical Trial.
Management of haemophilia A with inhibitors: A regional cross-talk.
Peyvandi F, Kavakli K, El-Beshlawy A, Rangarajan S. Peyvandi F, et al. Among authors: el beshlawy a. Haemophilia. 2022 Nov;28(6):950-961. doi: 10.1111/hae.14638. Epub 2022 Jul 22. Haemophilia. 2022. PMID: 35868021 Free PMC article. Review.
Development of a Thalassemia International Prognostic Scoring System (TIPSS).
Vitrano A, Musallam KM, Meloni A, Karimi M, Daar S, Ricchi P, Costantini S, Vlachaki E, Di Marco V, El-Beshlawy A, Hajipour M, Ansari SH, Filosa A, Ceci A, Singer ST, Naserullah ZA, Pepe A, Cademartiri F, Pollina SA, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A; International Working Group on Thalassemia (IWG-THAL). Vitrano A, et al. Among authors: el beshlawy a. Blood Cells Mol Dis. 2023 Mar;99:102710. doi: 10.1016/j.bcmd.2022.102710. Epub 2022 Nov 25. Blood Cells Mol Dis. 2023. PMID: 36463683 Review.
Recent trends in treatment of thalassemia.
El-Beshlawy A, El-Ghamrawy M. El-Beshlawy A, et al. Blood Cells Mol Dis. 2019 May;76:53-58. doi: 10.1016/j.bcmd.2019.01.006. Epub 2019 Feb 4. Blood Cells Mol Dis. 2019. PMID: 30792169 Review.
Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise.
Verma IC, El-Beshlawy A, Tylki-Szymańska A, Martins A, Duan YL, Collin-Histed T, van der Linde MS, Mansour R, Dũng VC, Mistry PK. Verma IC, et al. Among authors: el beshlawy a. Orphanet J Rare Dis. 2022 Apr 4;17(1):87. doi: 10.1186/s13023-022-02192-1. Orphanet J Rare Dis. 2022. PMID: 35369888 Free PMC article. Review.
A complication risk score to evaluate clinical severity of thalassaemia syndromes.
Vitrano A, Meloni A, Addario Pollina W, Karimi M, El-Beshlawy A, Hajipour M, Di Marco V, Hussain Ansari S, Filosa A, Ricchi P, Ceci A, Daar S, Titi Singer S, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Bonifazi F, Vichinsky E, Maggio A. Vitrano A, et al. Among authors: el beshlawy a. Br J Haematol. 2021 Feb;192(3):626-633. doi: 10.1111/bjh.17203. Epub 2020 Nov 20. Br J Haematol. 2021. PMID: 33216983 Free article.
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A. Maggio A, et al. Among authors: el beshlawy a. Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9. Lancet Haematol. 2020. PMID: 32470438 Clinical Trial.
101 results